Imfinzi® (durvalumab) showed a sustained overall survival benefit in 1st-line extensive-stage small cell lung cancer in the phase iii caspian trial

Detailed results from an updated analysis of the phase iii caspian trial showed astrazeneca’s imfinzi in combination with a choice of chemotherapies,
AXDX Ratings Summary
AXDX Quant Ranking